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Abstract Characterizing the biological effects of meta-
bolic transformations (or biotransformation) is one of the
key steps in developing safe and effective pharmaceu-
ticals. Sulfate conjugation, one of the major phase II
biotransformations, is the focus of this study. While this
biotransformation typically facilitates excretion of metab-
olites by making the compounds more water soluble,
sulfation may also lead to bioactivation, producing car-
cinogenic products. The end result, excretion or bioacti-
vation, depends on the structural features of the sulfation
sites, so obtaining the structure of the sulfated metabo-
lites is critically important. We describe herein a very
simple, high-throughput procedure for using mass spec-
trometry to identify the structure—and thus the biological
fate—of sulfated metabolites. We have chemically
synthesized and analyzed libraries of compounds repre-
senting all the biologically relevant types of sulfation
products, and using the mass spectral data, the structural
features present in these analytes can be reliably de-
termined, with a 97% success rate. This work represents
the first example of a high-throughput analysis that can
identify the structure of sulfated metabolites and predict
their biological effects.
Keywords Mass spectrometry . ICP-MS . Bioanalytical
methods . Pharmaceuticals . Biological samples .
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Introduction
The study of drug metabolism is one of the critical steps in
drug development [1–4]. At physiological conditions,
drugs undergo a variety of biotransformations, which
produce metabolites with different chemical structures. The
resulting metabolites differ in both pharmacological and
toxicological properties compared to their parent drugs [1].
Therefore, to identify and characterize the structures and
properties of drug metabolites formed in vivo, an extensive
investigation of the structures generated by biotransforma-
tion is required.
Sulfate conjugation (sulfation) is one of the most im-
portant phase II reactions that occurs during the biotrans-
formation of a variety of structurally diverse endogenous
compounds, xenobiotics, and drugs [5–9]. During this
process, a sulfonate moiety (SO3) is transferred from the
donor 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to
the substrates through the catalysis of sulfotransferase
enzymes, resulting in sulfated products [10]. Sulfation is
generally considered as a detoxification pathway, because
the sulfated products are more water-soluble; this facilitates
their elimination from the body [11–13]. However, sulfa-
tion can also lead to the bioactivation of certain type of
compounds which include benzylic, allylic alcohols and
aromatic hydroxylamines. Sulfated products of these com-
pounds can undergo loss of HSO
4 , resulting in reactive
electrophilic carbocation or nitrenium ion intermediates,
which covalently bind to cellular macromolecules, leading
to mutagenicity and carcinogenicity [6, 14, 15]. The
production of the electrophilic intermediates relies on the
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Tel.: +1-785-8643015structural feature of sulfation sites, as shown in Fig. 1.
Under physiological conditions, the sulfate anions in
substrates a–c in Fig. 1 act as good leaving groups to
form resonance-stabilized intermediates [6, 14]. For the
other types of sulfated products in Fig. 1, this process is not
favorable due to instability of cation products.
The biological sulfation of tamoxifen is one example
that demonstrates how the sulfation site dictates the
biological fate of the molecule. Tamoxifen is a pharma-
ceutical that is widely used in the treatment and prevention
of breast cancer. It is hydroxylated during phase I
metabolism to generate two products: 4-hydroxytamoxifen
(4-OH-TAM) and alpha-hydroxytamoxifen (α-OH-TAM).
The sulfation of 4-OH-TAM and that of α-OH-TAM have
completely different biological effects. The sulfation of
4-OH-TAM, which occurs at a phenol site (as in Fig. 1),
leads to detoxification, whereas the sulfation of α-OH-
TAM, which involves sulfation of a benzylic alcohol (as in
Fig. 1a), leads to bioactivation [16, 17]. This example
(along with many others) demonstrates the fact that the
biological effects of sulfation can be determined by char-
acterizing the sulfation site of the substrate.
It is widely known that aromatic or aliphatic hydroxyl
and amine groups are the major sites in molecules that can
be sulfated during metabolism [18]. However, identifying
the sulfation sites can be difficult because many potential
sulfation sites can be produced or modified during phase-I
biotransformations [5]. For example, hydroxyl groups can
be added to a benzene ring or carbon chain through
aromatic or aliphatic hydroxylation, generating new po-
tential sulfation sites as in the tamoxifen example. An
amine group can be changed to a hydroxylamine group
through N-oxidation [1], which modifies the structural
feature of the potential sulfation site. Since these new sites
are formed in vivo, characterizing the biological effect of
their sulfation can be problematic. It is thus essential to
develop a method that can characterize the sulfation sites of
unknown sulfated metabolites. With this information, the
biological effect of sulfation can be estimated, and the
properties of sulfated metabolites can be characterized.
Analytical techniques such as NMR spectroscopy and
mass spectrometry have been utilized to identify sulfated
metabolites [19–31]. NMR is a powerful technique that can
not only detect sulfated metabolites [20, 21, 24], but also
help to determine the position of sulfation in the substrate
molecules [19, 22, 23]. However, due to the relatively high
sample requirements, the complexity of data analysis, and
the need to characterize purified compounds, the applica-
tion of NMR in identification and characterization of drug
metabolites is limited in high-throughput metabolite
profiling. Compared to NMR, mass spectrometry is more
widely used in drug metabolite identification, due to its
high selectivity and sensitivity, low detection limit, and
ability to analyze mixtures [32]. It is known that mass
spectrometry can identify sulfation by detecting the 80 Da
mass increase in MS mode, or the characteristic ions in
MS/MS mode [21, 25–31]. However, limited information
about structural features of sulfation sites currently can
be obtained from MS/MS analysis, with the well-known
exception that the product ion m/z 97 (HSO
4 ) can be used
to differentiate alicyclic sulfates from aromatic sulfates
[25, 26].
In order to facilitate the identification of sulfation sites
in pharmaceuticals, we developed a mass spectrometry-
based protocol that differentiates between the biologically
relevant sulfation sites. After completing the studies on
Fig. 1 Mechanism of forming
bioactive carbocation or nitre-
nium ion intermediates from
sulfated products. Substrates a, b
and c undergo the bioactivation
process while d–g do not.
a sulfated benzylic alcohol;
b sulfated allylic alcohol;
c sulfated aromatic hydroxyl-
amine; d) sulfated aliphatic alco-
hol; e sulfated phenol; f sulfated
aliphatic amine; g sulfated
aromatic amine
667several classes of sulfated products, a set of rules was
developed to predict the sulfation sites. With these pre-
diction rules, structural feature of sulfation sites can be
determined by detecting MS/MS fragmentation pathways
of their corresponding sulfated products. With the struc-
tural information of sulfation sites, the two key different
biological effects of sulfation, “detoxification” and “bio-
activation”, can be differentiated, based on literature pre-
cedence that links the type of sulfation to its biological fate.
Based on that information, relevant properties of sulfated
products can be estimated.
Experimental
Reagents Sulfates and sulfamates which include 4-nitro-
catechol sulfate dipotassium salt, L-ascorbic acid 2-sulfate
dipotassium salt, indoxyl sulfate potassium salt, β-estra-
diol 3-sulfate sodium salt, potassium 4-nitrophenyl sulfate,
β-Estradiol 3-sulfate sodium salt, 5-Br-4-Cl-3-indolyl
sulfate potassium salt, 4-methylumbelliferyl sulfate potas-
sium salt, 2-aminoethyl hydrogen sulfate, poly (vinyl
sulfate) potassium salt, D-glucose 6-sulfate potassium salt,
chondroitin disaccharide Δdi-6S sodium salt, N-acetyl-
glucosamine 6-sulfate sodium salt, N-cyclohexylsulfamic
acid, 3-hydroxypropyl-sulfamic acid monopotassium salt,
D-glucosamine 2-sulfate sodium salt, and butyl-sulfamic
acid were purchased from Sigma-Aldrich (St. Louis, MO).
One sulfamate, 4-methylphenyl- sulfamic acid, was pur-
chased from Scientific Exchange, Inc. (Center Ossipee,
NH). (R)(+)-α-phenethylsulfamic acid was purchased
from Norse Laboratories (Newbury Park, CA).
The benzylic alcohols, allylic alcohols, hydroxylamines
which include (R)-(+)-α-methyl-2-naphthalenemethanol,
benzyl alcohol, (R)-1-phenyl-2-propen-1-ol, 4-chloro-2-
methylbenzyl alcohol, 3-ethoxybenzyl alcohol, 2-ethoxy-
benzyl alcohol, 4-ethoxybenzyl alcohol, crotyl alcohol,
furfuryl alcohol, N-methylhydroxylamine hydrochloride,
N-isopropylhydroxylamine hydrochloride, N-cyclohexyl-
hydroxylamine hydrochloride, N, N-diethylhydroxylamine
and N-benzoyl-N-phenylhydroxylamine were purchased
from Sigma-Aldrich (St. Louis, MO). These benzylic
alcohols, allylic alcohols, and hydroxylamines were uti-
lized to synthesize their corresponding sulfated products.
The other reagents used in the sulfation of alcohols and
hydroxylamines were also purchased from Sigma-Aldrich
(St. Louis, MO).
Sulfation of benzylic, allylic alcohols and tertiary hydro-
xylamines Sulfated products were prepared based on slight
modifications to a previous protocol [33] by dissolving
1.0 equivalent (5.0 mmol) of the substrate in 5.0 ml
dimethylformamide (DMF) and adding sulfur trioxide-
dimethylformamide complex (DMF-SO3 5.5 mmol) and
Fig. 2 Structures of selected sulfated compounds a sulfated aromatic alcohols or enols; b sulfated aliphatic alcohols with β hydrogens on
sp
3carbons; c sulfated benzylic or allylic alcohols; d sulfated hydroxylamines; e sulfated amines
668pyridine (5.5 mmol). The reaction mixture was stirred at
40 °C for 1 h. H2O (35 ml) was added to the product
solution, and the product was extracted with 3×15 mL
ethyl acetate (EtOAc). Evaporation of the solvent afforded
the corresponding sulfated product.
Sulfation of secondary hydroxylamines To a dry THF
(10 ml) solution of NaH (10.0 mmol) was added secondary
hydroxylamines (5 mmol) at 0 °C. Then the solution was
stirred at room temperature for 2 h, followed by reaction
with DMF-SO3 (5.0 mmol) overnight. The corresponding
sulfated products were obtained by evaporation of THF.
Sample pretreatment Sulfated compounds that were pur-
chased were dissolved to a final concentration of 1.0×10
−4
M with 50% MeOH/ 50% H2O, and directly injected
into the mass spectrometer. Sulfated benzylic and allylic
alcohols and tertiary hydroxylamines were prepared by
diluting 10 μl of the liquid product by 100 fold with
50% MeOH/50% H2O, and then injected to the mass
spectrometer. Sulfated secondary hydroxylamines were
prepared by dissolving 10 mg solid product in 1.0 ml 50%
MeOH/ 50% H2O, followed by injection into the mass
spectrometer.
Fig. 3 Characteristic (-) ESI-
MS/MS data for compounds in
this study: a sulfated aromatic
alcohol, from group a; b sulfated
aliphatic alcohol with β hydro-
gen on sp
3carbon, from group b;
c sulfated benzylic alcohol, from
group c; d sulfated aliphatic
hydroxylamine, from group d;
e sulfated aromatic hydroxyl-
amine, from group d; f sulfated
aliphatic amine, from group e;
g sulfated aromatic amine, from
group e
669Mass spectrometry The mass spectra were recorded using
a Quattro Ultima (Waters Corp., Milford, MA) triple
quadrupole mass spectrometer equipped with an electro-
spray ionization source. Data was acquired in the negative
ion mode using a capillary voltage of 2.80 kV and a cone
voltage was 45 V. The source temperature and desolvation
gas temperature were 80 and 150 °C, respectively. Argon
is used as the collision gas, and the pressure in collision
cell is 1.7E(−3) mbar. The collision energy applied in MS/
MS for all the samples was 35 eV.
Results and discussion
The structures of the sulfated products are in Fig. 2. These
compounds are representative of different types of sulfated
products that are produced by sulfation at different sites.
Mass spectrometric studies were conducted in the negative
ion mode since sulfated products are deprotonated at
physiological pH [11, 15]. The common product ions
from the MS/MS experiments are summarized in Table 1.
As the table indicates, common product ions include m/z
[M-H-80], m/z 80, m/z 96 and m/z 97. The presence of m/z
[M-H-80], m/z 96 or m/z 97 ions are quite dependent on the
site of sulfation. The presence of the negative ion with m/z
80, however, is common in the fragmentation of almost
every type of sulfated products, so it is less helpful in
identification of sulfation sites. Thus this ion, m/z 80, is
used to identify sulfation sites when no other characteristic
ions can be detected. Based on the MS/MS data, each type
of sulfated product possesses a characteristic fragmentation
pathway, which is described below. An example of MS/MS
data for each type of sulfated product is provided in Fig. 3
with the characteristic ion labeled by an asterisk.
Table 1 Characteristic fragmentation of selected sulfated products
Group No. Chemical name Abundance of characteristic ions in MS/MS (%)
m/z [M-80]
- m/z 80 m/z 96 m/z 97
a 1 4-nitrocatechol sulfate 100
a –––
2 L-ascorbic acid 2-sulfate 31
a –––
3 Indoxyl sulfate 24
a 52 ––
4 4-nitrophenyl sulfate 100
a –––
5 β-estradiol 3-sulfate 100
a –––
6 5-Br-4-Cl-3-indolyl sulfate 47
a 59 ––
7 4-methylumbelliferyl sulfate 100
a –––
b 8 2-aminoethyl hydrogen sulfate – 100 18 67
a
9 Poly (vinyl sulfate) –– – 97
a
10 D-glucose 6-sulfate –– – 100
a
11 Chondroitin disaccharide Δdi-6S –– – 31
a
12 N-acetylglucosamine 6-sulfate –– – 93
a
c 13 2-naphthalenemethanol, α-methyl- sulfate – 6.7 7.3
a 100
14 Benzyl sulfate – 16 100
a –
15 (R)-1-phenyl-2-propen-1-sulfate – 26 100
a 12
16 4-Cl-2-methylbenzyl sulfate –– 100
a 95
17 3-ethoxybenzyl sulfate – 100 13
a 6.4
18 2-ethoxybenzyl sulfate – 100 17
a 8.5
19 4-ethoxybenzyl sulfate – 100 20
a 8.7
20 crotyl sulfate – 55 91
a 50
21 furfuryl sulfate –– 53
a 39
d 22 N-methyl-hydroxylamine-O-sulfonic acid – 100 73
a 9.2
23 N-isopropyl- hydroxylamine-O-sulfonic acid – 68 100
a 5.1
24 N-cyclohexyl-hydroxylamine-O-Sulfonic acid – 27 100
a 11
25 N,N-diethyl-hydroxylamine-O-sulfonic acid – 92 100
a 19
26 N-benzoyl-N-phenyl-hydroxylamine-O-sulfonic acid –– 100
a –
e 27 N-cyclohexylsulfamic acid – 100
a ––
28 4-methylphenyl-Sulfamic acid – 100
a ––
29 3-hydroxypropyl-sulfamic acid – 100
a ––
30 D-glucosamine 2-sulfate – 100
a ––
31 butyl-sulfamic acid – 100
a ––
32 (R)(+)-α-phenethylsulfamic acid – 100
a ––
*A threshold of 5.0% is used for the relative abundance of characteristic ions. The long dash (–) means that the characteristic ion can not be
detected or the relative abundance is below 5.0%
aRepresents the specific characteristic ion of each group that can help to identify the sulfation site
670Group a: sulfated aromatic alcohols or enols
Compounds 1–7 are sulfated aromatic alcohols or enols.
For these compounds, the sulfate group is attached to an
sp
2 carbon (benzene ring or double bond). These sulfated
products share the same fragmentation pathway by under-
going the neutral lossof 80 Da, andforming a characteristic
ion at m/z [M-H-80], as seen in Fig. 3a. After undergoing
the neutral loss of SO3, phenoxide or enolic anions are
formed, and the negative charge is resonance stabilized, as
shown in Scheme 1 [33].
The second group of sulfated products originates from
the sulfation of aliphatic alcohols: compounds 8–12. For
these species, the sulfate group is attached to an sp
3 carbon.
All sulfated products of this type can produce the
characteristic ion m/z 97 in MS/MS, and one example is
shown in Fig. 3b. The ion m/z 97 is generated when the
proton from the β carbon is transferred to the sulfate
moiety, and the C-O bond is broken to form a bisulfate
anion [33]. See scheme 2.
This rearrangement occurs via an energetically acces-
sible six-membered ring transition state, and a stable
neutral product is formed. As a result, this fragmentation is
predominant in the MS/MS data of this group of sulfated
products. The mechanism shows that the availability of a
β hydrogen on an sp
3 carbon is required for this frag-
mentation. Unlike compounds in group a, neutral loss of
80 Da is not observed from this group of compounds. This
is likely due to the fact that the product ion that would be
generated from loss of 80 Da (SO3) is not resonance
stabilized, so the loss is not favorable. Compound 8 is a
special case because it gives a characteristic ion with m/z
96, in addition to m/z 97. The relevant mechanism for
this loss is addressed in the discussion of compounds in
group d.
Group c: sulfated benzylic or allylic alcohols
In the third group of sulfated compounds (13–21), each
contains a sulfate group attached to benzylic or allylic
carbon. All the compounds in this group produce a
characteristic ion with m/z 96. An example of an MS/MS
data for this type is shown in Fig. 3c. The characteristic ion
is produced by homolytic cleavage, producing benzylic or
allylic radicals. The radical is resonance stabilized, which
is demonstrated in Scheme 3 [33].
In addition to m/z 96, the negative ion m/z 97 can also be
obtained for some of the compounds in this category. For
example, compounds 13 and 16 both have an abundant
peak at m/z 97, due to the availability of a hydrogen on the
sp
3 carbon in close proximity to the sulfate group. Even
though compound 13 is a benzylic sulfate, a hydrogen
attached to the β sp
3 carbon is present. Therefore, just
like compounds in group b, it undergoes a rearrangement
to form the ion, m/z 97. Compound 16 possesses a methyl
group in the ortho position, and the availability of hydro-
gen attached to the sp
3 carbon in methyl group enables a
similar rearrangement (eight-membered ring) to form the
product ion, m/z 97, as illustrated in Scheme 4. Even
though β hydrogens are available in other benzylic and
allylic sulfates in this group, the fragmentation to produce
m/z 97 is not as favorable, since the hydrogens are on the
sp
2 hybridized carbons. The neutral loss of 80 Da is not
favorable either, because the product ion that would be
generated from such a loss is not resonance stabilized.
Group d: sulfated hydroxylamines
The fourth group of sulfated products originates from
sulfation of hydroxylamines, and as a result, the sulfate
group is directly attached to the amine: See compounds 22–
26. All the sulfated products of this group can produce the
characteristic ion m/z 96, and examples of MS/MS data are
shown in Fig. 3. A characteristic ion with m/z 96 can be
obtained for sulfated products originating from both
aliphatic (Fig. 3d) and aromatic (Fig. 3e) hydroxylamines.
For these sulfated compounds, homolytic cleavage is
favorable. This is due to the small electronegativity dif-
ference (about 0.5) between N and O, compared to elec-
tronegativity difference of around 1.0 for C –N and O-S
[34]. The small electronegativity difference causes the
electrons to be split equally (homolytic cleavage) between
the oxygen and nitrogen when the bond breaks, instead of
both electrons moving onto the oxygen or nitrogen, which
wouldbethecaseduringheterolyticcleavage.InScheme 5,
the mechanism of this homolytic cleavage is depicted. An
amine radical is formed as the product.
This mechanism can also be used to explain the presence
of the ion with m/z 96 in the MS/MS spectrum of
compound 8. Scheme 6 shows how this ion is produced
from compound 8. In this case, homolytic cleavage can be
used to distribute a single electron onto the nitrogen.
O S
O
O
-O
S
O
O
O
-O O O O
+
m/z [M-H-80]
-
Scheme 1 Sulfated aromatic alcohols or enols (group a) dissociate to produce a characteristic ion with neutral loss of 80 Da. Group b:
sulfated aliphatic alcohols with β hydrogens on sp
3carbons
O
S
O-
H R2
R1 O
O
R1
R2
+ S HO
O
O
O-
m/z 97
Scheme 2 Sulfated aliphatic alcohols (group b) produce the
characteristic ion m/z 97
671Compounds that contain a nitrogen two carbons away
from the sulfation site, like this one, could also produce m/z
96 as a product ion.
Group e: sulfated amines
The last group of sulfated products, sulfamates, originates
from the sulfation of amines. Compounds 27–32 belong to
this type. The only characteristic ion for this type of
sulfated products is the negative ion, m/z 80. This char-
acteristic ion can be obtained from fragmentation of
sulfated products originating from both aliphatic amines
(Fig. 3f) and aromatic amines (Fig. 3g). This group of
sulfated products has another type of bond, a N-S bond,
that has a small electronegativity difference between the
two atoms (0.5) [34], making the homolytic cleavage
between the nitrogen and sulfur favorable. The mechanism
that shows production of m/z 80 is illustrated in Scheme 7.
No other fragmentation pathway is as favorable as this
homolytic cleavage pathway, making m/z 80 the predomi-
nant ion in all of the MS/MS data for these compounds.
Prediction rules
For each type of sulfated product, there is a predominant
fragmentation pathway that results in a characteristic
product ion during MS/MS fragmentation. The specific
characteristic ion for each group is obtained from every
sulfated product in that group, as shown in Table 1: the ion
with the neutral loss of 80 Da can be seen in MS/MS
spectrum of every sulfated product in group a; an ion with
m/z 97 can be detected in all the MS/MS data of group b
compounds; an ion with m/z 96 can be obtained from MS/
MS data of all the sulfated products of both group c and
group d. A negative ion with m/z 80 can always be found in
MS/MS data of sulfated products in group e.
We have shown that characteristic fragmentation path-
ways of sulfated products are dependent upon the structural
features of the sulfation sites. Conversely, relevant struc-
tural information of sulfation sites can be obtained by
determining characteristic fragmentation pathways or char-
acteristic ions. To facilitate this information transformation,
a set of prediction rules is described as follows:
1. If the characteristic ion with a neutral loss of 80 Da can
be detected, this indicates that the sulfate group is
attached to an sp
2 carbon, the sulfated product is
therefore produced by the sulfation of a phenol or an
enol.
2. If the characteristic ion with m/z 96 can be detected, the
sulfated product is produced by sulfation of a benzylic
or allylic alcohol, or a hydroxylamine.
3. If the characteristic ion with m/z 97 can be obtained,
and it is more abundant than the ion, m/z 96 (if it is
detected), the sulfate group is attached to an sp
3
carbon. This is the sulfated product produced by
sulfation of aliphatic alcohols with an available β
hydrogen attached to an sp
3 carbon;
4. If none of the ions, m/z [M-H-80]
−, m/z 96, or m/z 97
can be detected, and only the ion m/z 80 is observed,
then the sulfated product is produced by sulfation of
an amine.
There are occasions when the conditions in rule 2 and 3
might both be observed. For example, both of these apply
to compound 13, which suggests that the sulfation site is
not only an alcohol with available β hydrogen (on an sp
3
OS
O
O
O- + O S
O
O
O-
m/z 96
Scheme 3 Sulfated benzylic and allylic alcohols (group c) produce the characteristic ion m/z 96
Cl
O
S
-O H
O
O
Cl
+ S HO
O
O
O-
m/z 97
Scheme 4 Fragmentation mechanism producing m/z 97 from
compound 16
N
R1
R2
O S
O
O
O- N
R1
R2
+ OS
O
O
O-
m/z 96
Scheme 5 Sulfated hydroxylamines (group d) produce the charac-
teristic ion m/z 96
O
H2N
S
O
O
O- NH2 + OS
O
O
O- +
m/z 96
 
Scheme 6 Fragmentation mechanism producing m/z 96 from
compound 8
R NH S
O
O
O- R NH + S
O
O
O-
m/z 80
Scheme 7 Sulfated amines (group e) produce the characteristic ion
m/z 80
672carbon), but also a benzylic or allylic alcohol; and this
estimation is consistent with the actual structure of
compound 13. Among the selected 32 sulfated products,
31 of them follow the proposed prediction rules. The
exception, compound 8, possesses an amine group in the β
position. The amine at this position enables the compound
undergo the fragmentation pathway to produce ion with
m/z 96 (see scheme 6). In this case, rule 2 incorrectly
predicts the sulfation site for compound 8. As a result, the
obtained data in Table 1 demonstrates a 97% (31/32=0.97)
success rate of these prediction rules.
Potential application of the prediction rules
in characterizing unknown sulfated metabolites
As one of the major phase II biotransformations, sulfate
conjugation is involved in the metabolism of an enormous
range of substrates [5]. In general, sulfation is a detoxifi-
cation or deactivation pathway, but it can also bioactivate
the substrate molecules when sulfation sites are benzylic,
allylic alcohols (group c) or aromatic hydroxylamines
(group d) [6, 8, 14]. According to the prediction rules
developed herein, sulfation at any of these sites will
generate products that produce the ion m/z 96 in MS/MS,
so the structural feature of the sulfation sites can be
determined by rule 2. Sulfation of other sites, like phenols,
aliphatic alcohols or amines, will cause other characteristic
ions to appear in MS/MS data. Therefore, the sulfation sites
can be determined by rule 1, 3 or 4. In these cases, sulfation
facilitates detoxification.
With the proposed prediction rules, biological effects
of sulfation can be determined, and the properties of
sulfated metabolites can be estimated. Figure 4 demon-
strates how the proposed method works to characterize
unknown sulfated metabolites. Since high-quality MS/MS
data is a necessary prerequisite of using this method, if
the metabolite is present in a complex biological matrix,
some mass spectral optimization may be necessary. After
obtaining reliable (-)ESI-MS/MS data on the unknown
sulfated metabolite, the prediction rules are used to de-
termine sulfation site by identifying the characteristic ions
present in the MS/MS data. If the MS/MS data matches
rule 1, 3 or 4 (instead of rule 2), the sulfation sites can be
phenols (or enols), aliphatic alcohols (with β hydrogen
on sp
3 carbon) or amines. In these cases, the sulfation
undergoes a detoxification pathway and the sulfated
metabolite is more easily eliminated, compared to the
parent drug. If the MS/MS data is consistent with rule 2,
the sulfation site should be benzylic, allylic alcohols or
hydroxylamines. This would indicate that the sulfation
might follow a bioactivation pathway, and lead to carci-
nogenic sulfated products. One potential caveat to this
second condition is that a few nontoxic sulfated metabo-
lites that have structures similar to compound 8, might also
produce the characteristic ion with m/z 96, following the
mechanism in Scheme 6. Another possible drawback of
this characterization is that the diagnostic ion m/z 96 does
not discriminate between sulfated products of aliphatic
and aromatic hydroxylamines; and thus far only aromatic
hydroxylamines have been proven to be toxic. However,
distinguishing between aromatic and aliphatic hydroxyl-
amines is not critically important because sulfated aliphatic
hydroxylamines are rather uncommon metabolites. While
it is possible that a few compounds could be misassigned as
“toxic”, none of the sulfated metabolites that are known to
Fig. 4 The method for characterizing unknown sulfated metabolites
673be bioactivated would be misdiagnosed as “nontoxic”,a s
demonstrated herein.
Conclusion
A method was developed to determine the structural
features of sulfation sites, by detecting the characteristic
fragmentation pathway of the corresponding sulfated prod-
ucts in (-) ESI-MS/MS. By summarizing MS/MS data from
five different types of sulfated products originating from
different sulfation sites, their characteristic fragmentation
pathways and characteristic ions were determined. Based
on this information, a set of prediction rules was developed
to transfer information about the fragmentation pathway of
sulfated products to the structural features of the sulfation
site. As a result, the proposed prediction rules can be
applied in drug metabolite profiling to characterize sulfa-
tion sites, to further estimate the biological effect of
sulfation, and to evaluate relevant properties of sulfated
metabolites.
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